Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

NCT06960577 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06960577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06960577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2025
Completion date
August 30, 2028
Enrollment
150 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

cisplatin, doxorubicin, gemcitabine, immune checkpoint inhibitors, methotrexate, urinary bladder neoplasms, vinblastine